Abstract
The increasing worldwide prevalence of obesity creates a need for novel antiobesity treatments having outcomes superior to current drugs [1]. Modulation of CNS histaminergic activity represents a new mechanism because blocking postsynaptic H1 receptors induces weight gain [2], while H3 antagonists cause weight loss or prevent weight gain [1, 3–5]. Imidazole-based H3 antagonists may inhibit drug metabolism, potentially instigating undesirable drug-drug interactions [6]. Therefore, we evaluated the non-imidazolebased H3 antagonist A-331440 ({4¢-[3-(3(R)-(dimethylamino)-pyrrolidin-1-yl)-propoxy]-biphenyl-4-carbonitrile}, Fig. 1 [7]) in diet-induced or genetic (ob/ob) mouse obesity models. Inflamm. res. 53, Supplement 1 (2004) S47–S48 1023-3830/04/01S47-02 DOI 10.1007/s00011-003-0322-5
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
